Medical University Vienna

Department of Clinical Pharmacology, Medical University Vienna
The Department of Clinical Pharmacology Vienna was established in 1992 as an independent department within the Medical University Vienna. It is based in one of Europe’s largest medical centres, the 2.200-bed Vienna General Hospital.

Our goal is to provide expertise and infrastructure for state of the art research on patients and healthy volunteers, in collaboration with the clinical departments at the hospital and other teaching hospitals in the Vienna region. Our strength is in complex labor-, equipment- and time-intensive studies exceeding the simple requirements for bioequivalence or standard tolerability testing.

The department is experienced in performing Phase I-IV clinical trials, sponsored by renowned pharmaceutical companies, or funded by academic grants. The successful completion and publication of over 600 drug trials (academic and industry-sponsored) in the period 1995-2011 ensures ample GCP (good clinical practice) experience including cooperation with health authorities, government- and European Medicines Agency (EMA) inspectors, and the Ethics Committee. Only recently, our group performed three first-in-men studies for replication deficient influenza vaccines (H1N1 and H5N1) as a clinical partner in two EU funded FP6 research grants.

www.meduniwien.ac.at/klpharm/

 

MICHAEL WOLZT | MD

Current position: Senior consultant, Vienna General Hospital; Head, Cardiovascular Medicine at the Department of Clinical Pharmacology; Director, Clinical Trials Coordination Centre of the Medical University of Vienna.

Research focus: The scientific interest covers different clinical aspects of inflammation, vascular function, thrombosis, and metabolism. He serves as vice-chair at the Ethics Committee of the Medical University of Vienna, and is named European expert to the EMA. He is director of the Austrian Clinical Research Infrastructures Network ATCRIN, which is partner in the FP7-funded consortium ECRIN and co-ordinates the IMI-JU project EMTRAIN. Investigator in first-in-human studies for replication deficient influenza viruses and inactivated whole virus Vero cell-derived Ross River virus vaccine.